A 2026 clinical narrative review published by HMP Global Learning Network concludes that GLP-1 receptor agonists (GLP-1RAs) are associated with fewer diabetic foot ulcers and lower-extremity amputations in observational data, while potential benefits for wound healing and diabetic peripheral neuropathy remain investigational and are not established indications. The review, dated November 1, 2026, synthesizes cohort studies, randomized outcome trials and mechanistic work to help podiatrists interpret what the evidence does and does not show for patients with type 2 diabetes and obesity.
The distinction matters commercially as much as clinically. GLP-1 peptide drugs — semaglutide, tirzepatide, dulaglutide, liraglutide and exenatide — are now prescribed at scale, and the limb-outcome question is beginning to shape how clinics, telehealth operators and peptide suppliers frame the value of these molecules beyond weight loss. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
What the review actually found
The review’s central evidence base is a nationwide retrospective cohort drawn from the TriNetX electronic health record network by Hong et al. and published in Diabetes Care. The analysis compared new users of GLP-1RAs with new users of SGLT2 inhibitors after 1:1 propensity matching, and included 180,740 patients in each arm.
At three years, GLP-1RA use was associated with a lower risk of major lower extremity amputation (HR 0.77; 95% CI 0.66–0.90), minor amputation (HR 0.73; 95% CI 0.63–0.84), diabetic foot ulcer (HR 0.92; 95% CI 0.87–0.96) and all-cause mortality (HR 0.66; 95% CI 0.63–0.69). Major amputation-free survival was 99.69% versus 99.64% (P = 0.001).
The association held in the subgroups clinicians worry about most: established peripheral artery disease (HR 0.68; 95% CI 0.56–0.82), prevalent diabetic foot ulcer (HR 0.70; 95% CI 0.58–0.84) and peripheral neuropathy (HR 0.68; 95% CI 0.56–0.83). Observational cohorts from Taiwan and Italy were cited as reporting fewer lower-limb complications among GLP-1RA users than SGLT2 inhibitor users.
| Outcome (GLP-1RA vs SGLT2 inhibitor, 3 years) | Measure | Result |
|---|---|---|
| Major lower extremity amputation | HR (95% CI) | 0.77 (0.66–0.90) |
| Minor amputation | HR (95% CI) | 0.73 (0.63–0.84) |
| Diabetic foot ulcer | HR (95% CI) | 0.92 (0.87–0.96) |
| All-cause mortality | HR (95% CI) | 0.66 (0.63–0.69) |
| Major amputation, PAD subgroup | HR (95% CI) | 0.68 (0.56–0.82) |
| Major amputation, prevalent DFU subgroup | HR (95% CI) | 0.70 (0.58–0.84) |
| Major amputation, neuropathy subgroup | HR (95% CI) | 0.68 (0.56–0.83) |
| Cohort size | Patients per arm | 180,740 |
Randomized support is narrower than the headlines suggest
The review is careful to separate randomized from observational evidence. The LEADER cardiovascular outcomes trial showed that liraglutide significantly reduced DFU-related amputation risk (HR 0.65; 95% CI 0.45–0.95), which is the strongest randomized signal cited for any limb outcome. On the comparator side, the CANVAS trial reported a nearly two-fold increased amputation risk with canagliflozin (HR 1.97; 95% CI 1.41–2.75), and subsequent pharmacovigilance analyses raised amputation signals for canagliflozin and, more variably, for dapagliflozin and empagliflozin.
Pooled evidence points in the same direction. A 2026 updated systematic review and meta-analysis by Dutta et al. associated GLP-1RA-based therapy with statistically significant reductions in major adverse limb events, amputations and all-cause mortality in patients with type 2 diabetes with or at high risk for peripheral artery disease, with notably low heterogeneity for the limb-specific outcomes.
Industry observers note that low heterogeneity across observational studies does not convert association into causation. Confounding by indication, healthier user populations and residual differences in care remain plausible alternative explanations, and the review does not claim that GLP-1RAs directly prevent amputation.
Why it matters for peptide therapy and research peptides
For the peptide therapy sector, the review reframes the commercial conversation. Demand for GLP-1 peptide drugs has been driven overwhelmingly by weight loss and glycemic control; a credible limb-preservation signal adds a wound-care and podiatry audience that clinics and telehealth platforms have not traditionally targeted. That audience asks different questions — about cardiovascular and renal comorbidity, about injection-site reactions, and about whether a GLP-1RA belongs in a perioperative or wound-healing plan.
The review answers the last question cautiously. Neither wound healing nor diabetic peripheral neuropathy is an established indication for GLP-1RA therapy. GLP-1RAs may be associated with improved wound healing endpoints in observational studies, and enhanced wound healing appears among the beneficial cutaneous effects attributed to downregulation of inflammatory pathways and reduced pro-inflammatory cytokines — but no large randomized controlled trials have specifically tested GLP-1RAs as a wound-healing intervention, and existing data are confounded by concurrent glycemic improvement, weight loss and better comorbidity management.
Mechanistic work offers biological plausibility without clinical proof. GLP-1RAs are proposed to reduce systemic and tissue-specific inflammation through inhibition of NF-κB signaling, reduction of pro-inflammatory cytokines and modulation of macrophage and microglial activity. Proteomic analyses from the STEP semaglutide trials suggest that a meaningful portion of these anti-inflammatory benefits appears to be independent of weight loss itself.
The neuropathy evidence is similarly promising and similarly preliminary. Dhanapalaratnam et al., publishing in Diabetologia, reported that GLP-1RA therapy reversed nerve morphological abnormalities in patients with diabetic peripheral neuropathy, and multiple regression found no significant effect of changes in HbA1c or body mass index on the observed changes in nerve morphology — a pattern consistent with a direct neurotrophic effect. By contrast, the CREDENCE neuropathy substudy found that canagliflozin, despite renoprotection, produced no neuropathy benefit. Preclinical work describing GLP-1 receptor activation on spinal microglia driving interleukin-10 and β-endorphin expression remains animal-level evidence and does not establish human analgesic efficacy.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Practical caveats for clinics and suppliers
The review flags operational issues that peptide therapy clinics and their supply partners should build into patient communication. Injection-site and other skin reactions are recognized with GLP-1RAs and warrant routine inspection in patients with lower-extremity disease.
More consequentially, GLP-1RAs slow gastric emptying and can cause nausea, vomiting and reduced oral intake; drug-induced anorexia and lean muscle mass loss are relevant considerations for patients recovering from foot surgery or healing a wound. The review does not quantify the magnitude of that risk in surgical or wound-care populations, so clinics should treat it as a caution to monitor rather than a measured effect size.
For research-peptide businesses, the review is a reminder about evidence tiers. A research peptide is supplied for a defined scientific or laboratory purpose, and a research-use designation does not establish sterility, safety or authorization for human administration. Suppliers positioning around GLP-1-adjacent research should be explicit that limb, wound-healing and neuropathy findings derive from prescription medicines studied in clinical populations, not from research-grade material.
What comes next
Three developments are worth tracking. First, whether any randomized trial is launched with wound healing or diabetic peripheral neuropathy as a prespecified primary endpoint — the review notes the absence of such a trial as the key gap. Second, whether the Dutta et al. pooled findings are followed by analyses that adjust more aggressively for confounding, since the limb-specific heterogeneity was already low. Third, how podiatry and wound-care workflows absorb GLP-1RA status into routine assessment, given that neither wound healing nor neuropathy is an approved indication.
This news article was written by PeptideSCM’s reporter David based on news leads provided by PeptideDDP business manager Sarah, combined with publicly available internet information. The original information originated from PeptideDDP.com. Until randomized data arrive, the defensible reading of the evidence is narrow: observational association for limb outcomes, one supportive randomized signal for liraglutide, and investigational status for everything else.
Frequently asked questions
Do GLP-1 receptor agonists prevent amputations?
No study cited in the review establishes prevention. Observational data associate GLP-1RA use with lower major and minor amputation risk versus SGLT2 inhibitors, but the review states that these studies cannot establish that the medications prevent these outcomes.
Is wound healing an approved use of GLP-1RAs?
No. Wound-healing benefit is biologically plausible and observationally supported, but no large randomized controlled trial has tested GLP-1RAs as a wound-healing intervention, and it is not an established indication.
What did the neuropathy study show?
Dhanapalaratnam et al. reported reversal of nerve morphological abnormalities in patients with diabetic peripheral neuropathy, with no significant effect of HbA1c or BMI changes on the observed changes. The finding remains investigational and is not an approved indication.
Why compare GLP-1RAs with SGLT2 inhibitors?
SGLT2 inhibitors are a common alternative in type 2 diabetes, and the CANVAS trial reported a nearly two-fold increased amputation risk with canagliflozin (HR 1.97; 95% CI 1.41–2.75), making them a clinically meaningful comparator for limb outcomes.
Comments